Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Garrett JT, Chakrabarty A, Arteaga CL
Oncotarget. 2011 2 (12): 1314-21

PMID: 22248929 · PMCID: PMC3282088 · DOI:10.18632/oncotarget.409

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) axis regulates essential cellular functions including cell survival, proliferation, metabolism, migration, and angiogenesis. The PI3K pathway is activated in human cancers by mutation, amplification, and deletion of genes encoding components of this pathway. The critical role of PI3K in cancer has led to the development of drugs targeting the effector mechanisms of this signaling network. Recent studies have shown that inhibition at multiple levels of the PI3K pathway results in FOXO-dependent feedback reactivation of several receptor tyrosine kinases (RTKs) which, in turn, limit the sustained inhibition of this pathway and attenuates the action of therapeutic antagonists. This suggests that if used as single agents, PI3K pathway inhibitors may have limited clinical activity. We propose herein that to successfully target the output of the PI3K pathway in cancer cells, combination therapies that hinder these compensatory mechanisms should be used. Thus, combination therapies that target RTKs, PI3K, and mTOR activities may be required to maximize the clinical benefit derived from treatment with these inhibitors.

MeSH Terms (13)

Animals Antineoplastic Agents Forkhead Box Protein O1 Forkhead Transcription Factors Humans Mice Neoplasms Phosphatidylinositol 3-Kinase Protein Kinase Inhibitors Proto-Oncogene Proteins c-akt Receptor Protein-Tyrosine Kinases Signal Transduction TOR Serine-Threonine Kinases

Connections (1)

This publication is referenced by other Labnodes entities:

Links